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Exemplified by cancer cells’ preference for glycolysis, for example, the Warburg effect, altered metabolism in tumorigenesis
has emerged as an important aspect of cancer in the past 10–20 years. Whether due to changes in regulatory tumor suppres-
sors/oncogenes or by acting as metabolic oncogenes themselves, enzymes involved in the complex network of metabolic pathways
are being studied to understand their role and assess their utility as therapeutic targets. Conversion of glycolytic intermediate 3-
phosphoglycerate into phosphohydroxypyruvate by the enzyme phosphoglycerate dehydrogenase (PHGDH)—a rate-limiting step
in the conversion of 3-phosphoglycerate to serine—represents one such mechanism. Forgotten since classic animal studies in the
1980s, the role of PHGDH as a potential therapeutic target and putative metabolic oncogene has recently reemerged following
publication of two prominent papers near-simultaneously in 2011. Since that time, numerous studies and a host of metabolic
explanationshavebeenputforwardinanattempttounderstandtheresultsobserved.Inthispaper,Ireviewthehistoricprogression
ofourunderstandingoftheroleofPHGDHincancerfromtheearlyworkbySnellthroughitsreemergenceandrisetoprominence,
culminating in an assessment of subsequent work and what it means for the future of PHGDH.
1. Introduction
As a genetic disease, cancer is primarily caused by mutations
in oncogenes and tumor suppressors, which serve to control
tissue homeostasis [1]. Altered function, in turn, leads to
deregulated mitogenic survival and growth of tumors that
frequently exhibit oncogene-activating genomic alterations
such as gene amplification or gain-of-function point muta-
tions.Tumorsmayalsoexhibittumor-suppressorinactivating
mutations, including gene deletions, loss-of-function point
mutations, or epigenetic silencing [1]. Taken together, these
changes enable cells to acquire “stereotypical capabilities”
termed by some scholars “hallmarks of malignancy” [1, 2].
Overthepast10–20years,increasingevidencehasshownthat
the majority of oncogenes and tumor suppressors also play
a role in the regulation of metabolism. Mutations serve to
“orchestrate nutrient utilization in a manner that facilitates
cell survival and growth” [1]—a phenomenon exemplified in
the work of Warburg et al. [3, 4].
The “Warburg effect” named in his honor describes a
process wherein cancer cells preferentially use fermentative
glycolysis-based glucose metabolism instead of entering the
tricarboxylicacidcycle(TCA)andsubsequentelectrontrans-
port chain, even under aerobic conditions [3–6]. The causes
and benefits of the effect have been the focus of study for
manyyears[5,7],yetdespiteadvancesinbiochemicalunder-
standing,thephysiological“reason”remainsunclear[6].One
hypothesis suggests that cancer cell proliferation is not
l i m i t edb yA T Pp r od u cti o nb u tr a th e rb yth ea b il i t yo fc e ll st o
synthesizelipids,nucleicacids,andproteinsneededtobolster
an expanding biomass [6]. Preferential aerobic glycolysis
would allow cancer cells to adapt metabolism to satisfy a
resultantly increased biosynthetic need—an idea supported
by evidence which suggests that the enzyme pyruvate kinase,
catalyzing the final step in glycolysis as shown in Figure 1,
is inhibited in tumorigenic cells [8]. The observed selection
toward reduced pyruvate kinase activity may further enable
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Figure 1: Schematic of glycolysis in a mammalian cell showing a branch point wherein glycolytic intermediate 3-phosphoglycerate can be
channeled into a serine biosynthetic pathway via the activity of putative metabolic oncogene phosphoglycerate dehydrogenase (red), adapted
from Hamanaka and Chandel [15].
upstream glycolytic intermediates (e.g., 3-phosphoglycerate)
tobedivertedintoothermetabolicpathwaysusedtoproduce
theadditionallipids,nucleicacids,andproteinsthatMullarky
et al. [6] describe [8]. Blockage of the constituent metabolic
activitiesinexperimentalsystemshasbeenfoundtosuppress
tumor cell growth in vitro and in vivo [1].
Metabolic reprograming in tumorigenic cells is not lim-
ited to deregulationby oncogenes and tumorsuppressors but
can also result from genomic modifications to the metabolic
enzymes themselves, independently contributing to biomass
accumulationandproliferativegrowth[9–14].Thislaterclass
of facilitative oncogenes has started to generate an increasing
amount of interest in recent years as researchers return to
classic studies to uncover the potential utility of seemingly
overlooked historic results and apply them to human tumor
growth. It is hoped that, by “shedding light on the biological
basis of malignancy,” new applications of old discoveries may
lead to the development of novel cancer therapeutics [1]. To
be an attractive candidate for cancer therapy, there must be
a significant difference between the requirements for a par-
ticular enzyme’s activity in cancer and normally proliferating
cells[15].Itisherethatputativemetaboliconcogenesbecome
“both interesting and important” given their propensity to
display metabolic activities that “differ significantly [and], in
some cases profoundly,” from those of enzymes in normal
cells [1].
One example is the conversion of glycolytic interme-
diate 3-phosphoglycerate into phosphohydroxypyruvate by
t h ee n z y m ep h o s p h o g l y c e r a t ed e h y d r o g e n a s e( P H G D H ) — a
rate-limiting step in the conversion of 3-phosphoglycerate
to serine (Figures 1 and 2)[ 15]. In the paper that follows,
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F i g u r e2 :S c h e m a t i co ft h em a j o rp a t h w a y so fs e r i n em e t a b o l i s mi nam a m m a l i a nl i v e r .S h o w ni nr e d ,p h o s p h o g l y c e r a t ed e h y d r o g e n a s e ,t h e
first enzyme branching from glycolysis in a three-step serine biosynthetic pathway uses NAD
+ as a cofactor to oxidize 3-phosphoglycerate
into phosphohydroxypyruvate. The product is then subsequently converted into phosphoserine via transamination by phosphoserine
aminotransferase and, ultimately, to serine via phosphate ester hydrolysis and the enzyme phosphoserine phosphatase. Classic work by
Snell [16] suggests preferential upregulation of the serine hydroxymethyltransferase branch, leading to nucleic acid synthesis coupled with
downregulation of the serine dehydratase and serine aminotransferase branches in some subsets of cancer cells, adapted from Snell [16].
t h er o l eo fP H G D Hi nc a n c e rf r o mt h ec l a s s i cw o r ko fS n e l l
et al. [16–20]i nt h e1 9 8 0 st h r o u g hi t sr e e m e r g e n c ea n dr i s e
to prominence in 2011 with near simultaneous publications
by Possemato et al. [21]a n dL o c a s a l ee ta l .[ 8], culminating
in an assessment of subsequent work and what it means for
the future of PHGDH as a potential therapeutic target and
putative metabolic oncogene.
2. Classic Studies: Animal Models and
Early Work by Snell
In a review of serine metabolism published in 1984, Snell [16]
provides what is widely regarded as one of the first in-depth
discussionsoftheroleofPHGDHintumorigeniccells.Citing
an u m b e ro fp r i o rl a b o r a t o r yr e s u l t s[ 27], he notes that the
activitiesofenzymesinvolvedinserinebiosynthesishadbeen
previously assessed in rat neoplastic tissue [16]. Specifically,
enzymatic activity of PHGDH assayed in four transplantable
hepatomas (Morris series: 7794B, 7793, 9121, and 5123TC)
was elevated 1.7–10.6 times relative to control livers in rats
o ft h es a m es t r a i n[ 16, 27]. Reductions in dietary protein
induced adaptive increases in PHGDH activity in control
animalsandhealthyportionsofthetumor-bearinghostliver,
presumablyduetohomeostaticeffortstosupportdiminished
n u c l e i ca n da m i n oa c i ds u p p l i e s ,b u tf a i l e dt oh a v ea n ye ff e c t
ontheenzymeinhepatomacells[27].Snell[16]h ypothesized
thattheobservationmaysuggestalossofregulatoryfunction
or cancerous enzymatic adaptation. Seemingly hesitant to
make such a strong claim, he further noted that the obser-
vation may also reflect physiological independence between
intramuscularly implanted hepatomas and the innate portal
circulation of otherwise healthy rats [16]. In the numerous
assays performed by Davis et al. [27] in the Morris Lab, only
twoinvolvinghepatomas7793and5123TCwerethesubjectof
multipleanalyses,bothofwhichconsistentlyfoundelevations
of PHGDH relative to healthy liver tissue. In 5123TC it was
furthershownthattheoverallrateofserinebiosynthesisfrom
carbon-labeled 3-phosphoglycerate closely correlated with
the activity of PHGDH, indicating that enhanced activity of
PHGDHinthefourhepatomaswasresponsibleforincreased
serine biosynthetic capacity—a conclusion, which Snell [16]
suggests, “needs to be treated with caution in view of the
above comment on protein content and, in any case, only
relates to a very limited number and range of tumors.” In
the years that followed, Snell’s tone began to change as his
own research at the Laboratory for Experimental Oncology
at Indiana University School of Medicine led to the first real
inclination of just how “limited” PHGDH activity in cancer
cells might be.
Two years later, Snell and Weber [18]p u b l i s h e dap a p e r
entitled “Enzymatic Imbalance in Serine Metabolism in Rat
Hepatomas” which showed that the activity of PHGDH was
indeed increased in tissues with high cell-renewal capacity4 Journal of Oncology
in addition to elevations in neonatal and regenerating liver
cells. Elevations in hepatomas were markedly higher still
(8.8–11.9-fold in slow-growing hepatomas and up to 50.8–
75.5-foldinfast-growinghepatomas),suggestinganapparent
correlation of PHGDH activity with the tumorigenic rate of
growth and an important association with both neoplastic
transformation (slow-growth tumor) and progression (fast-
growth tumor) [18]. Relative to increased activity in neonatal
(10-fold when adjusted for differences in cellularity between
adult and neonatal livers) and regenerating liver (2.6-fold)
cells, the enhanced activity observed, particularly in fast-
growing tumor cells, was thought to point to a specificity in
the changes of PHGDH activity in cancer cells. Examination
of downstream enzyme activity revealed parallel increases
in the activity of serine hydroxymethyltransferase and an
absence of serine dehydratase and serine aminotransferase
contributions (Figure 2), resulting in preferential shunting
o fg l u c o s ev i at h es e r i n eb i o s y n t h e t i cp a t h w a yt o w a r dt h e
formation of nucleic acid bases [18]. Such coordinated alter-
ations coupled with the previous work of Davis et al. [27]
and Snell [16] would seem to suggest that cancer cells (at
least in hepatomas) have induced an enzymatic imbalance to
meet tumorigenic needs that places PHGDH in a regulatory
position.Capableofdivertingglucose-derivedcarbontoward
serinebiosynthesisand,bywayofhydroxymethyltransferase,
toward nucleotide formation, such a change confers a selec-
tive growth advantage to neoplastic cells relative to their
somatic counterparts [18]. Repeated transplantations of the
hepatoma lines in vivo did not alter the effect [18], leading to
what Snell et al. [19] would later describe as robust evidence
for“reprogrammingofgeneexpression”inrathepatomacells.
Some 19 months later in July 1987, Snell et al. [19]p u b -
lishedagainthistimelookingattheactivitiesofPHGDHand
hydroxymethyltransferase during the transition of hepatoma
cells from a resting, nonproliferative state to induced prolif-
erative growth. During the different phases of fast-growing
hepatomacellsinculture,enzymeactivitiesincreasedrapidly
to reach peaks at 24h during the early exponential or state-
transitional phase and then declined as cells reached higher
confluency and entered the plateau phase of growth [19]. The
burgeoning hypothesis of coordinated regulation was again
confirmed and, in fact, further supported by a series of sub-
sequent experiments in which matched changes in carbon-
labeledserineincorporationintonucleicacidswereobserved
[19].
F i n a l l yi nJ a n u a r y1 9 8 8 ,S n e l le ta l .[ 20]p u b l i s h e dt h e i r
f o u r t ha n dfi n a lp a p e ro nt h er o l eo fP H G D Hi nc a n c e rc e l l s ,
firmly calling into question Snell [16]’s 1984 supposition on
the “very limited number and range of tumors” to which
the observed reprogramming of gene expression applied
[16, 19, 20]. Their work showed that the patterns of serine
metabolism in tumors established in the group’s previous
studies [16–18]—enhanced PHGDH and serine hydrox-
ymethyltransferase, absent serine dehydratase and serine
aminotransferase—were consistent in both a transplantable
rat sarcoma model and in human colon carcinoma [20].
In tissues lacking serine dehydratase and serine amino-
transferase, such as skeletal muscle where the rat sarcoma
model was assayed, preferential reorientation for nucleotide
formation cannot be achieved by deletion of nonexistent
competing enzymes and must instead rely only on substan-
tiallyincreasedactivityofserinehydroxymethyltransferasein
tumors [17, 20]. This final piece of work becomes significant
movingforward,forasSnelletal.[20]importantlynote,allof
their previous studies relied on transplantable rat tumors in
animal model systems. However, “if the patterns are to have
significance [...],p a r t i c u l a r l yi nr e l a t i o nt ot h ed e v e l o p m e n t
of strategies for enzyme-targeted anticancer drug therapy,
thentheymustalsobedemonstratedinhumancancers”[20].
Much like the results from the rat sarcoma, the activity of
PHGDH was found to be elevated 10-fold, and that of serine
hydroxymethyltransferase nearly 5-fold, in tumors relative
to healthy colon mucosa. Competing enzymes of serine
utilization were absent from both [20].
3. Expression in Humans
Following Snell et al.’s final publication in 1988 [20], the
group’s work shifted to consider the therapeutic role of serine
hydroxymethyltransferase,leavingthediscussionofPHGDH
all but abandoned for more than a decade. It is not until
the work of Cho et al. [22] published in March 2000 that its
potential utility as a metabolic oncogene begins to apprecia-
bly reemerge. Building on the need to establish expression
in human cancer cells, Cho et al. [22] looked at nucleotide
sequence and differential expression of the human PHGDH
gene.CitingworkbyAchourietal.[28]thatreportedsuccess-
ful cloning of the first mammalian PHGDH gene from a rat
hepatoma in 1997, Cho et al. [22]u s e d3 0 0c D N Ac l o n e sr a n -
domly sequenced from a 𝜆 ZAP human Jurkat T-cell cDNA
library to look for similarity to the known rat PHGDH gene.
O n e8 5 2b pc l o n es h o w e dp a r t i a ls i m i l a r i t yt ot h e3
򸀠-region
and was subsequently used to rescreen the library as a novel
probe [22]. Of five hybridization-positive clones, one con-
tained an insert 2,478bp long. Comparison to other known
PHGDH sequences and 3D modeling allowed for the assign-
ment of substrate-binding, nucleotide-binding, and regula-
tory domains. The overall sequence was found to share 94%
homology with rat PHGDH [28]a n d9 3 %h o m o l o g yw i t h
murine PHGDH [22].
When the sequence was compared via individual func-
tional domains, the nucleotide-binding domain, containing
a consensus Gly-Xaa-Gly-Xaa-Xaa-Gly-Xaa17-Asp sequence
known to be involved in binding the adenosine portion of
NAD
+, showed the highest degree of homology [22]. The C-
terminal regulatory domain was more variable, particularly
in length, but did not contain alterations considered impor-
tant for allosteric control [29, 30].
Tissue distribution of PHGDH-specific mRNA was then
analyzed using a
32P-labeled version of the 2,478bp PHGDH
cDNA probe on a human multiple tissue northern blot assay
[22]. Two transcripts, approximately 2,100bp and 710bp in
size, were detected. The dominant 2.1kb mRNA transcript
was found at high levels in the prostate, testis, ovary, brain,
liver, kidney, and pancreas. Lower levels were found in the
mucosal lining of the colon and, weakly, in the thymus, small
intestine,andheart[22].Incontrast,Achourietal.[28]foundJournal of Oncology 5
asingle2.1kbmRNAderivedfromtheliverofaratdetectable
only under conditions of a protein-free, carbohydrate-rich
diet. Pointing to this discrepancy, Cho et al. [22]n o t et h a t
dietaryregulationakintothatmentionedbySnellin1984[16]
may not be significant in human tissues given that the 2.1kb
mRNA was found expressed at high levels in the human liver
even under normal conditions. The secondary 710bp mRNA
was detected as a minor transcript in most of the tissues
where the dominant transcript was observed with notably
higherlevelsrelativetothedominanttranscriptintheheart.It
was the only transcript found in human skeletal muscle [22].
Taken together, the normal physiological findings of Cho
et al. [22] suggest that expression of human PHGDH is not
limited to tissues with a high proliferative capacity but rather
expressed in a tissue-specific manner. The minor 710bp
mRNA transcript is thought to potentially reflect differen-
tial splicing or use of a secondary internal (2.1kb intron-
contained) transcriptional start [22].
Cho et al. [22] then sought to determine what happens
to the differential expression of PHGDH-specific mRNA in
malignant human tumor cells and whether the anticipated
elevation in PHGDH protein expression is due to upregu-
lation of PHGDH mRNA at the transcriptional level or is
instead the result of modifications in enzymatic characteris-
ticssuchas𝐾𝑚,𝑉 max,and/orstability .Akintotheiranalysisof
normal tissue, Cho et al. [22]u s e dan o r t h e r nb l o ta s s a yw i t h
PHGDH cDNA to reveal that the dominant 2.1kb mRNA
transcript was detectable in most continuously growing
tumor cells. PHGDH transcriptional expression was identi-
fied in several human leukemias (Jurkat, MOLT-3, HL-60,
U937, and THP-1), T-cell lymphoblastic lymphoma (Sup-T1),
colon adenocarcinoma (COLO 320DM), epithelioid carci-
noma (HeLa S3), and murine lymphoma (BW5147.G.1.4)
[22]. The highest levels of expression were observed in
COLO 320DM and BW5147.G.1.4. The physiological role
for the minor transcript remains unclear, but, of note, its
transcriptional expression in human tumors paralleled that
of the dominant transcript [22]. On the whole, the results
of Cho et al. [22] establish that upregulation of PHGDH at
the transcriptional level may be responsible for the elevated
enzymatic activity reported in neoplasia by Snell et al. [18–
20] and suggest that their assertion of application to human
expression can be generalized to include most leukemias and
lymphomas of human and murine origin.
4. Reemergence of Phosphoglycerate
Dehydrogenase: Breast Cancer
Studies of human PHGDH began to appear in subsequent
years, prior to prominently reemerging in 2011 with the
w o r ko fP o s s e m a t oe ta l .[ 21]a n dL o c a s a l ee ta l .[ 8]. How-
ever, prior to their respective publications in Nature and
Nature Genetics,t h ew o r ko fP o l l a r ie ta l .[ 23] set the stage.
Metastatic transcriptional expression revealed by Cho et al.
[22] led to the identification of enhanced serine production
in bone metastatic breast cancer cells and simulation of
osteoclastogenesis[23].Subsequent(andprior)contributions
are summarized in Table 1.
Highlighting the incurable nature and significant mor-
bidity of bone metastatic disease, Pollari et al. [23]u s e d
breast cancer cell line MDA-MD-231 (derived from an estro-
gen receptor-negative strain) to model breast cancer bone
metastasis in vivo via intracardiac inoculation of immunod-
eficient mice. Comparison of parental MDA-MD-231 and an
enhanced daughter variant with heightened metastatic abil-
ities, MDA-MB-231(SA), revealed genetic aberrations that
were highly conserved between the two lines [23]. Genome-
wide expression profiles pointed to mere 315 genes (1.7% of
genes) that were more than 2.5-fold upregulated and 198
genes (1.1% of genes) that were more than 2.5-fold downreg-
ulated in the highly metastatic variant relative to the parental
strand. Purported pathway associations for the upregulated
genes pointed to changes in organic acid, amino acid, and
amine metabolism in addition to alterations to nitrogen
compound biosynthetic processes—the most significantly
enriched of which included the pathway for glycine, serine,
and threonine metabolism. Three genes and their corre-
sponding enzymes are involved in the processes of all
three: PHGDH, phosphoserine aminotransferase (PSAT1),
and phosphoserine phosphatase (PSPH) (Figure 2). Relative
to the parental metastatic cell line, highly metastatic MDA-
MB-231(SA) daughter cells exhibited upregulations of 5.1-,
5.8-, and 2.6-fold, respectively. A serine/alanine/cysteine/-
threonine transporter known as SLC1A4 was likewise ele-
vated 3.4-fold with overexpression of each confirmed by
quantitative RT-PCR (mRNA) and Western blot (protein)
assays. Subsequent statistical quantification using repeat
probesetsfurthershowedthatwhilePHGDHexpressionwas
significantly higher (𝑃 < 0.001)i ns t r o n g l yv e r s u sw e a k l y
metastatic cells, PSAT1 expression was not significant and
PSPH failed to correlate with metastatic ability at all [23].
Pollari et al. [23] concluded their analysis with an assess-
ment of PHGDH, PSAT1, and PSPH expression relative to
t i m et or e l a p s ei n3 6 8h u m a nc l i n i c a lb r e a s tc a n c e rs a m p l e
c e l l sa sw e l la sr e l a t i v et oo v e r a l ls u r v i v a lt i m ei n3 9 3b r e a s t
cancersamplecells.Theirsecondaryanalysispresentsthefirst
well-documented assessment of clinical outcomes associated
with serine biosynthetic elevation in cancer cells. What they
found was a statistically significant association between high
PHGDH expression and shorter time to relapse (𝑃 < 0.001)
in addition to shorter overall survival time (𝑃 = 0.002).
Further assessment for “clinically relevant features” in a sub-
set of 251 samples pointed to additional associations between
enzymatic PHGDH and PSAT1 expression and several rec-
ognized risk features, including estrogen and progesterone
receptor negative status, mutated p53, higher tumor grade,
heightenedexpressionofthecellproliferationmarkersPCNA
and Ki-67, and higher levels of ERBB2 [23].
In August 2011, Possemato et al. [21]p u b l i s h e dal e t t e r
in Nature. With the stated aim of identifying metabolic
genes required for tumorigenesis, Possemato et al. [21]c r o s s -
referenced known maps of metabolic pathways with the
KyotoEncyclopediaofGenesandGenomic(KEGG)database
to compile what they considered a “comprehensive list” of
2,752 genes encoding “all known human metabolic enzymes
and transporters.” Identified genes were scored on 3 criteria
to identify a “high-priority” set of 133 metabolic enzyme6 Journal of Oncology
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and transporter genes: (1) known to have high expression in
tumors versus normal tissue, (2) known to have high expres-
sion in aggressive breast cancer, and (3) known to be associ-
atedwiththestem-cellstate.Selectedcandidateshadtofittwo
of the three categories or be “at the top” of a given category.
Among the chosen 133 genes, Possemato et al. [21]c o n -
structed lentiviral short hairpin RNA (shRNA) vectors tar-
geting the respective genes with a median of 5 shRNA per
gene and used them to generate 2 libraries—1 targeting
transporters and control genes (235 distinct shRNA) and 1
targeting metabolic enzymes and control genes (516 distinct
shRNA). When the libraries were screened for shRNA that
b e c a m ed e p l e t e dd u r i n gb r e a s tc a n c e rt u m o rf o r m a t i o ni n
mice, 16 genes “hit” with at least 75% of the corresponding
shRNA targeting the respective genes. Expected targets (e.g.,
the mitochondrial ATP transporter VDAC1) “hit” as did
genes involved in control of oxidative stress, the pentose
phosphate pathway, glycolysis, proline biosynthesis, and ser-
ine biosynthesis. For 5 of the 16 original hits (including
PHGDH), 2 of the “scoring” shRNA were tested for their
effectontumorigenesis.Eachsuppressedtargetexpressionin
tumorformingbreastcancerculturedMCF10DCIS.comcells
and reduced the cell’s tumor-forming capacity [21].
Consultation of cancerous somatic genome-wide copy
number alterations reported in the work of Beroukhim et al.
[31]i na ne ff o r tt op r i o r i t i z eg e n e sr e v e a l e dt h a tPHGDH
exists in a region of chromosome 1p commonly amplified in
several types of cancer, including cancers of the breast and
skin (melanoma) [21]. None of the other hit genes coincided
with genomic regions of focal and recurrent copy number
gain.Moreover,threeshRNAthatscoredinthein vivo screen
also decreased PHGDH protein expression; two of differing
knockdown efficacies inhibited tumor growth [15].
The initial results of Possemato et al. [21]c o r r o b o -
rate the findings of Pollari et al. [23]w h o ,a sp r e v i o u s l y
described, reported elevated PHGDH mRNA levels in estro-
gen receptor-negative breast cancer cells. Cognizant of these
findings, Possemato et al. [21]c o n fi r m e dP o l l a r ie ta l . ’ s[ 23]
resultsinadistinctgeneexpressionsetbeforegoingontofind
that PHGDH was also elevated in estrogen receptor-negative
breast cancer relative to normal breast tissue. In an effort to
situate these observations within their larger body of work,
Possemato et al. [21] note that, of all the genes identified
as hits in their previous screen, PHGDH had the most sig-
n i fi c a n t l ye l e v a t e de x p r e s s i o ni ne s t r o g e nr e c e p t o r - n e g a t i v e
breast cancer cells. Among 82 human breast tumor samples
assessed in an immunohistochemical assay (not discussed in
this review) PHGDH protein levels significantly correlated
with estrogen receptor-negative status [21]. In what became
o n eo ft h ep a p e r ’ sm o s th e a v i l yc i t e dr e s u l t s ,P o s s e m a t oe ta l .
[21] conclusively state that, relative to estrogen receptor-
positive breast tumors, estrogen receptor-negative tumors
have approximately 68% and 70% elevations of PHGDH,
respectively, at the mRNA and protein levels, accounting for
an estimated 20–25% of prevalent breast cancer cases and
as much as 50% of breast cancer deaths within 5 years of
diagnosis [32].
Turning to yet another line of evidence, the letter by
Possemato et al. [21] continues to note that, across a set of
8 breast cancer cell lines, 4 with copy number amplifications
of PHGDH had8–12-foldhigherPHGDHproteinexpression
relative to nontransformed cell lines (lacking gene-based
amplification). Where the subsidiary analysis becomes inter-
esting is in its secondary observation that PHGDH protein
levels were elevated in two estrogen receptor-negative cell
lines, lacking a PHGDH copy number gain [21]—a finding
which suggests that additional mechanisms beyond genomic
amplificationmustexisttopromoteupregulationofPHGDH
expression at reported mRNA and protein levels.
To better understand the metabolic consequences asso-
ciated with such increased PHGDH expression, Possemato
et al. [21]u s e dm e t a b o l i t ep r o fi l i n ga n da na n a l y s i so fs e r i n e
synthesis pathway flux to examine breast cancer cells with
and without PHGDH genomic amplification. Cell lines with
copy number gains (BT-20, MDA-MB-468, and HCC70)
experienced increased flux through the serine biosynthetic
pathway (Figure 2) relative to those without MDA-MB-231,
MCF7, and MCFC10A. Moreover, cell lines with elevated
PHGDH and high pathway flux were capable of enhancing
proliferationinmediumlackingserine,whilelineswithlower
levelsofPHGDHunderwentsignificantbluntingorcessation
of proliferation. Notably, RNAi-mediated suppression of
PHGDH resulted in reduced serine pathway flux in both
MDA-MB-468 (no amplification) and BT-20 (amplification)
cells. Conversely, in MCF10A human mammary cells engi-
neeredtooverexpressPHGDH,serinepathwayfluxincreased
tolevelssimilartothoseseeninconstitutivelyamplifiedcells.
Even in the absence of serine, the additional overexpression
of PHGDH in modified MCF10A cells was sufficient to
driveglucose-originatingfluxthroughthebiosyntheticserine
pathway [21].
In their penultimate experiment, Possemato et al. [21]
sought to determine whether PHGDH is required for cell
survival and growth in cells exhibiting increased PHGDH
expression. They observed that, in cells with high PHGDH
e x p r e s s i o n( w h e t h e ro rn o tt h e yh a dc o p yn u m b e rm u t a -
tions), RNAi-mediated suppression of PHGDH caused an
appreciable decrease in cell number and induced cell death
in the absence of apoptotic markers. In cells with established
tumorigenic growth, doxycycline treatment of inducible
shRNA reduced PHGDH protein levels in murine mammary
fat pad tumors established with transduced MDA-MD-468
cells at 25 days, indicating that PHGDH suppression can
adversely affect growth among established tumor cells [21].
Such seemingly contradictory results with respect to
serine flux presented a conundrum for Possemato et al. [21].
On the one hand, serine, as shown in Figure 2,i sac e n t r a l
metabolite in biosynthetic reactions for amino and nucleic
acidproduction;heightenedexpressionofPHGDHincancer
cells had been found to significantly enhance biosynthetic
serine pathway flux. On the other hand, the work of Posse-
mato et al. [21]t h u sf a rh a ds h o w nt h a tP H G D Hs u p p r e s s i o n
also inhibited proliferation in cells growing in media with
normal levels of extracellular serine (an amino acid which
can also be taken up). Supplementation with additional
serineorcell-permeablemethyl-serine-esterdidnotbluntthe
suppressive effect. Looking first for more obvious solutions,
Possemato et al. [21] confirmed that intra- and extracellular8 Journal of Oncology
serine were in equilibrium and that import of extracellular
serine was not defective in the cell lines considered. Then,
lacking an alternative explanation, they concluded that,
perhaps, serine production is not the only important role for
PHGDH in cancer cells [21].
Thus, in their final experiment for the paper, the
researchers sought to test the notion that PHGDH, PSAT1,
a n dP S P Hr e a c t i o n sm a yp r o d u c em e t a b o l i t e sb e y o n ds e r i n e
critical for cell proliferation [21]. They hypothesized that, in
cells with high PHGDH expression, the subsequent PSAT1
reaction might contribute a significant fraction of glutamate
to alpha-ketoglutarate (aKG) flux—a notion supported by
t h e i rfi n d i n gt h a tt h es e r i n ep a t h w a yp r o d u c e se q u i m o l a r
amounts of serine and aKG. If true, as will be discussed in
a subsequent section of the paper, serine biosynthesis would
play an important role in anaplerosis of glutamine-derived
carbon to the TCA. Consistent with this possibility, sup-
pression of PHGDH in MDA-MB-468 cells caused a large
reduction in levels of aKG. Moreover, of the major metabo-
lites measured, aKG had the most significant and largest
change upon PHGDH suppression, while serine levels were
notsignificantlyaffected.Confirmatorylabelingstudiesusing
U-
13C-glutamine further revealed that absolute flux from
glutaminetoaKGandtootherTCAintermediateswassignif-
icantly reduced in cells with RNAi-mediated suppression of
PHGDH [21]. In cells with high PHGDH expression, the ser-
ine biosynthetic pathway may be responsible for as much as
50% of the net conversion of glutamate to aKG. Suppression
of PHGDH would then result in a significant loss of TCA-
intermediate flux. Parallel labeling studies in cell lines with
PHGDH amplification relative to those without found that
flux through the serine biosynthetic pathway shunts 8-9%
of glycolytic flux toward serine production as compared to
1-2% in cell lines with low PHGDH expression [21]. Based
on this body of evidence, Possemato et al. [21]b e l i e v et h a t
increased flux through the serine biosynthetic pathway has
a major impact on aKG production but a smaller effect on
g l y c o l y s i sa n ds e r i n eb i o a v a i l a b i l i t yt ot u m o r i g e n i cc e l l s( a t
least in the breast) than previously observed.
5. Extension to Other Cancers
In their nearly concurrent publication in Nature Genetics
addressing PHGDH expression in melanoma cells, Locasale
et al. [8] challenge the conclusions of Possemato et al.
[21], suggesting that PHGDH directly diverts glycolytic flux,
thereby, contributing to oncogenesis in cancer cells. Rather
than a genomic database, Locasale et al. [8] began their
investigation by monitoring the time course of conversion
of U-
13C-glucose using targeted chromatography and mass
spectrometry in HEK293T cells. Labeled glucose was incor-
porated into 13 metabolites across multiple pathways over a
3 0m i ns p a n[ 8]. Importantly, flux to phosphoserine reached
steady state on a time scale similar to that of phospho-
enolpyruvate (Figures 1 and 2), suggesting comparable rel-
ative flux.
13C-phosphoserine labeling paralleled
13C-serine
labeling—data further corroborated by NMR experiments
which indicated that a “substantial fraction” of glucose is
diverted from 3-phosphoglycerate toward the conversion of
serineandglycineinthesecells.Tomeasurethetotalamount
of glucose-derived serine being made, Locasale et al. [8]
culturedcellsinuniformlylabeled
13C-glucoseandmeasured
metabolites in cell extracts using targeted chromatography
a n dm a s ss p e c t r o m e t r y .L a b e l e ds e r i n ea c c o u n t e df o ra b o u t
one-half with corresponding amounts of glucose incorpo-
ration detected in subsequent nucleotide and nucleoside
intermediate formation. Expression of PHGDH was verified
byWesternblot;Locasaleetal.[8]reportedanapproximately
30-fold increase in protein expression relative to nontumori-
genic cells (absent in MCF10a cells).
Indication of selective glucose diversion led to the notion
that there may be a context in which pressure exists for
tumorstoincreasePHGDHactivity[8];muchlikePossemato
et al. [21], Locasale et al. [8] wondered whether the mecha-
nism might involve genomic amplification (a copy number
gain) at the locus containing the PHGDH gene. To that end,
they identified PHGDH i nt h ew o r ko fS l a m o ne ta l .[ 33]a n d
noted that PHGDH was found in a region of chromosome 1p
(1p12) known to exhibit recurring copy number gains in 16%
of all cancers [8] .F u r t h e ri n s p e c t i o no ft h eg e n o m i cr e g i o n
encodingPHGDH revealedlocalizedamplificationwithinthe
codingregionofthegene.Inanefforttoverifythesefindings,
the researchers examined focal copy number gain using
fluorescence in situ hybridization (FISH) with an esophageal
squamous cell carcinoma line (T.T. cells) known to contain
amplification of PHGDH.S t a b l eP H G D Hk n o c k d o w nu s i n g
shRNA reduced the proliferation rate. Moving on to test
whether the decreased proliferation was due to reduced abil-
ity to utilize the serine biosynthetic pathway, Locasale et al.
[8] generated cell lines with reduced expression of PSAT1
and PSPH to find that shRNA-mediated knockdown of these
enzymes resulted in similarly diminished proliferation rates.
Echoing the need for human data first espoused by Snell
[16]a n dC h oe ta l .[ 22], Locasale et al. [8]r e t u r n e dt ot h e i r
PHGDH amplification results and noted that since amplifi-
cation in a single tumor type was most commonly found in
melanoma, it may be of use to consider PHGDH expression
and copy number gain in human melanoma tissue samples.
To that end, they used immunohistochemistry to measure
PHGDH expression and found that high expression (defined
by an IHC score > 1) was observed in 21% of samples. Cor-
responding copy number gains were detected with FISH in
as u b s a m p l eo f2 1o u to f4 2t u m o r sa s s a y e d .T oi n v e s t i g a t e
whether melanoma cell lines containing PHGDH amplifica-
tion would be sensitive to decreased expression of PHGDH,
cell lines with and without copy number gains were assessed
with a methodology similar to that of the studies con-
ducted by Possemato et al. [21]. Amplified cell lines revealed
decreased proliferation in response to reduced PHGDH,
while nonamplified lines did not change on PHGDH knock-
down. Verification of serine metabolic flux further showed
that each amplified line did contain appreciable conversion
of labeled glucose to serine. PHGDH knockdown reduced
phosphoserine levels in Sk-Me128 cells and globally altered
metabolite levels, including those of glycolytic intermediates.
More specifically, under PHGDH knockdown conditions,Journal of Oncology 9
heighted glycolytic metabolite levels were detected near the
point of diversion onto the serine biosynthetic pathway—the
results which Locasale et al. [8]t o o kt om e a nt h a tt h el e v e lo f
PHGDHexpressedinacellaltersglucosemetabolism(inSk-
Mel128 cells) by modulating entry of glycolytic intermediates
into serine metabolism.
H o w e v e r ,w h i l ec o p yn u m b e rg a i no ff e r so n em e c h a n i s m
to divert flux into serine biosynthesis, Locasale et al. [8]
also note that other mechanisms to elevate PHGDH expres-
sion likely exist and may be important in specific cancer
contexts. For example, pointing to the work of Possemato
et al. [21] which found that high PHGDH mRNA was
associated with poor prognosis in breast cancer, Locasale
et al. [8] undertook a bioinformatics analysis of multiple
tumor microarray datasets in breast cancer and found strong
associations (𝑃 < 0.0001) with several clinical parameters. In
an effort to validate and expand these results, Locasale et al.
[8] assessed PHGDH protein expression in 106 breast cancer
tumor samples using immunohistochemistry correlated with
mRNA expression to find that high PHGDH expression
associated significantly with triple-negative (𝑃 = 0.002)
and basal subtypes (𝑃 = 0.004)b u td i dn o ta s s o c i a t ew i t h
general parameters such as metastasis (as was previously
reported) or with tumor size. Consistent with a reliance of
a subset of breast cancers on PHGDH, protein expression
was required for growth in a panel of three (BT-20, SK-BR-3,
and MCF-7) breast cancer cell lines (including the BT-20 cell
line that carries amplification). Reduced PHGDH expression
decreased phosphoserine levels in PHGDH amplified BT-20
cells,whilenontumorigenicbreastcancerepithelialMCF-10a
cells did not require PHGDH for growth, exhibit alterations
in glycolysis on shRNA knockdown of PHGDH, or show
detectable labeling of phosphoserine from glucose [8].
Given the importance granted to these two papers and
the dense nature of the results that they report, it seems
prudenttotakeamomenttoreview.Bothstudiespublishedin
mid-2011 report that the gene encoding PHGDH is amplified
in a significant subset of human tumors and underscore
that diversion of glycolytic intermediates into the serine
biosynthetic pathway may contribute to tumorigenesis in
cancercells[5,8,21,34].ConvergenceonPHGDHhappened
through different means in different subsets of cancer-
derived laboratory cells, leading to different understandings
of the mechanisms involved. Nevertheless, whether using
functional genomics or metabolomics methods via Posse-
mato et al. [21]’s loss-of-function RNA-interference screen or
Locasale et al. [8]’s glucose-derived carbon flux, both groups
identified purported targets of interest and mined known
databases of cancer copy number alterations to determine
that PHGDH on chromosome 1p12 is amplified in some 6%
of breast cancers and 40% of melanomas. Beyond genomic
amplification, a larger fraction of tumors were found to have
elevated PHGDH protein levels, including 70% of estrogen
receptor-negative breast cancers. High PHGDH expression
(with or without genomic amplification) was associated with
dependence on the enzyme for growth either via serine
utilization or a hypothesized benefit of aKG to the TCA—
a phenomenon that Deberardinis [5] and Seton-Rogers [34]
describe as tumorigenic “addiction” to “flexible flux” [5, 8, 21,
34].
InaseriesofpapersthatfollowedLiuetal.[24],Jingetal.
[25]a n dN o he ta l .[ 26] extend these ideas to consider
PHGDH’s purported role in astrocytoma, cervical cancer
s q u a m o u sc e l lc a r c i n o m a ,a n dt r i p l en e g a t i v eb r e a s tc a n c e r
cells. Citing the work of Possemato et al. [21]a n dL o c a s a l e
et al. [8], Liu et al. [24] sought to determine whether the
effect also existed in glioma cells. Analysis of PHGDH levels
in specimens from glioma patients revealed that although
PHGDH is not normally expressed in healthy brain tissue,
significant elevations were observed in astrocytic tumors in
increasing correlation with progressively advanced tumor
grade. Mechanistic investigations revealed that inhibition
of PHGDH expression in glioma cells impaired prolifera-
tion, invasion, and tumorigenicity in vitro and in vivo.I n
nude mice injected with stable, PHGDH shRNA-silenced
glioma cells, overall survival was prolonged relative to mice
injected with wild-type cells. The oncogenic transcription
factor FOXM1 was also downregulated in PHGDH shRNA-
silenced glioma cells. Using liquid chromatography/liquid
chromatography-mass spectrometry, Liu et al. [24] identi-
fied PHGDH as a novel binding partner for FOXM1. The
interaction stabilized FOXM1 protein levels and sequentially
induced the expression of a series of oncogenes, including
MMP-2, VEGF, Chk2, and cyclin D1—a combined body of
evidence which may suggest additional roles for PHGDH in
glioma tumorigenesis beyond serine biosynthetic flux akin
to that described for aKG in a subset of breast cancer cells
by Possemato et al. [21]a n d ,i nt h i sc a s e ,p o t e n t i a l l yb e y o n d
metabolic functions themselves [24].
The work of Jing et al. [25]f o l l o w sas i m i l a rt r e n d
highlighting the role for PHGDH in cervical cancer. As with
tumorigenicbreast cancer, melanoma,and astrocytomacells,
PHGDH was more strongly expressed in cervical cancer
relative to normal cervical epithelium (72 versus 29%, 𝑃<
0.05)[ 25]. Expression levels positively correlated with serum
squamous cervical cancer antigen in squamous cell carci-
noma, a form of cervical cancer (𝑃 < 0.05)—both of
which also associated with tumor progression, stage, and
size (𝑃 < 0.05)[ 25]. Finally, the work of Noh et al. [26]
published in January 2014 echoes the work of Pollari et al.
[23] with estrogen receptor-negative breast cancer cells (later
corroborated and expanded in the work of Possemato et al.
[21]). Using six different subtypes of triple negative breast
cancer (TNBC), Noh et al. [26]a s s e m b l e dm i c r o a r r a y so f
formalin-fixedandparaffin-embeddedtissuefrom129TNBC
patients. Immunohistochemistry assays for enzymes of ser-
ine (and glycine) metabolism, including PHGDH, PSAT1,
PSPH, and serine hydroxymethyltransferase, and surrogate
markers for identification of molecular tumor type revealed
that, among TNBC tumors, basal marker-positive patients
exhibited increased expression of PHGDH relative to basal
marker-negative patients (𝑃 = 0.029). On the whole, protein
expressionofPHGDHtendedtobehighinpatientsclassified
as mixed or basal-like subtype and low in patients classified
as immune-related, molecular apocrine, or null subtype but
was not statistically different when considered across all six10 Journal of Oncology
TNBCtypes(𝑃 = 0.070).Amongmixedsubtypecases,89.3%
showed partial expression of basal markers in their mix [26].
6. Physiological Relevance of the Findings
Historic progression aside, the question remains “What do
these findings actually mean for the utility of PHGDH in
cancer cells?” The answer is not clear, rendering PHGDH a
fascinating and, at first glance, unintuitive metabolic target
in cancer [5] .K n o w nt oc a t a l y z ee n t r yi n t oa“ m e t a b o l i cs i d e
street, diverting flux away from the “superhighway” of tumor
cell glycolysis,” it would appear to reduce energy formation
from glucose in rapidly proliferating cells [5], yet as the
works of Warburg et al. [3, 4] and others have shown, cancer
metabolic pathophysiology is seldom so simple. PHGDH
copy number, transcriptional, and protein amplifications
havebeenshowninmultiplesubsetsofcancerouscells,clearly
indicating that some selective advantage is being attained.
W h i l et h ep r e c i s en a t u r eo ft h a ta d v a n t a g er e m a i n su n c l e a r
and, in fact, may differ across types of cancerous cells,
several hypotheses have been put forward. Metabolic path-
ways downstream from serine metabolism contribute to
growth, promoting biosynthesis and metabolic signaling
involvingthefolatepool,aminoacid/lipidintermediates,and
redox regulation [8]. The process of diverting glycolytic flux
out from 3-phosphoglycerate serves to further alter cellular
redox status via the oxidation of 3-phosphoglycerate and to
a i di nt h eg e n e r a t i o no fa K Gf r o mg l u t a m a t e — a l lo fw h i c h
a r er e p o r t e dt ob e n e fi tc e l l u l a rp r o l i f e r a t i o n[ 8].
Considered in more detail, the first and perhaps most
readily apparent benefit involves the products of serine
biosynthesis itself—de novo production of serine and, by
way of serine hydroxymethyltransferase, glycine from which
multiple amino and nucleic acids can be made. What is
interesting about this aspect of the pathway is that cells
grown in standard in vitro culture conditions consisting of
abundant extracellular serine have been found to be sensitive
to PHGDH knockdown [6]. Perhaps, as Mullarky et al.
[6] suggest, cells do not express the correct amino acid
transporterstoimportenoughserineorperhapshomeostatic
mechanisms regulating metabolic flux are not coupled to
extra- and intracellular serine pools. Whatever the reason,
de novo synthesis of an otherwise nonessential amino acid
preferentiallyoccurssuchthatinitsabsencecellproliferation
suffers or does not occur. This notion of dependency or
“addiction” to a “flexible flux” [5, 34]l e a d st os e v e r a lo ft h e
other hypothesized reasons and, consequentially, purported
benefits that heighted expression of PHGDH is likely to
confer.
Tying into the conversion of serine to glycine by the
enzyme serine hydroxymethyltransferase, the second notion
stems fromrecognitionthatthisconversionprovidesa major
source of methyl groups for the one carbon pools required
forbiosynthesisandDNAmethylation[5,6].Bycontributing
one-carbon units to the folate pool, serine biosynthesis
regulated by PHGDH effectively provides skeletons for the
synthesis of purines and pyrimidines (Figure 2), a conse-
quencethatledMullarkyetal.[6]toarguethatthenumerous
resultant contributions of PHGDH to biomass production
m a yh e l pt oe x p l a i np a r to fi t sp r o t u m o r i g e n i ce ff e c t .Th e
notionisnotentirelynew.TheworkdescribedbyPollarietal.
[23] found that, in breast tumors, expression of multiple
enzymes along the serine/glycine biosynthetic pathway was
associated with metastasis in mice and poor clinical out-
comes in humans. Moreover, as noted by DeBerardinis [5]
and shown by Nikiforov et al. [35] two isoforms of serine
hydroxymethyltransferase act as transcriptional targets for
the oncogene c-Myc with serine hydroxymethyltransferase
overexpression leading to stimulated proliferation in c-Myc-
deficient cells. At the same time, both serine and glycine are
abundant in the plasma, so as noted previously by Mullarky
etal.[6],itisnotimmediatelyapparentwhatcanbegainedby
upregulatingsynthesisattheexpenseofglycolysis,despitethe
observation that that is precisely what some cancerous cells
seem to do [5].
Perhaps the role of aKG used by Possemato et al. [21]
to explain their seemingly counterintuitive observation that
silencing PHGDH expression failed to deplete intracellular
serine can offer insight to the benefit gained. As mentioned
above, aKG is a metabolite produced via the transamina-
tion reaction of phosphoserine aminotransferase during the
conversion of phosphohydroxypyruvate to phosphoserine
(Figure 2). It is also the entry point through which glu-
tamine supplies carbon to the TCA cycle during cell growth,
thereby enabling production of many essential biosynthetic
precursors [5]. As noted by Possemato et al. [21], as much as
halfofallglutamine-derivedaKGinPHGDH-overexpressing
cells was generated via an offshoot of the PHGDH-regulated
serine biosynthetic pathway. The compelling implication,
supported by Possemato et al. [21], is that PGHDH could
act as a metabolic gatekeeper, aiding proliferative control of
both macromolecular biosynthesis downstream of glutamine
metabolism (cell growth) and serine-dependent DNA syn-
thesis (cell proliferation) [5]. Furthermore, as outlined by
Mullarky et al. [6], generation of aKG through the serine
biosynthetic pathway may help to alleviate ammonia toxicity
stemmingfromaminoacidcatabolism.aKGsynthesisviathe
serine biosynthetic pathway bypasses a mechanism wherein
glutamatederivedfromglutamineiscatabolizedbyglutamate
dehydrogenase to eventually derive aKG, producing a unit
of ammonia in the process [6]. Ammonia levels regulate
autophagy, and, as Mullarky et al. [6]a t t e s t ,i tw o u l db e
interesting to see whether cancer cells requiring PHGDH to
function have defects in autophagy after PHGDH knock-
down.
The suggestion that aKG synthesized from serine is
c r i t i c a lf o rt u m o rg r o w t hi sn o te a s yt ou n d e r s t a n df r o m
a metabolic point of view given the numerous potential
physiological sources of the compound [36]. It is generated
fromtransaminationofavarietyofaminoacidsandissynthe-
sized directly in the TCA cycle. Mullen and DeBerardinis [1]
seemingly agree, stating that cancer cells (at least in culture)
express a number of other highly active transaminases in
addition to PSAT1 which often account for the majority of
glutamine-derived aKG. It will be interesting to see as future
studies unfold why a subset of cancer cells appear to prefer-
entially use PSAT1 as a source for aKG. As for anaplerosisJournal of Oncology 11
propagating the TCA cycle, it is a role typically filled by
conversion of pyruvate to oxaloacetate (major reaction
involving formation of HCO3
−)a n dt h er e v e r s i b l et r a n s a m -
ination of aspartate to form oxaloacetate (including gener-
ation of glutamate and depletion of aKG) coupled with the
oxidation of glutamate back to aKG (glutamate + NAD
+ +
H2O → NH4
+ +a K G+N A D H+H
+) or the conversion
of propionyl-CoA to succinyl-CoA (propionyl-CoA + ATP +
HCO3
− → succinyl-CoA + ADP + Pi)i nt h e𝗽-oxidation
of fatty acids [36]. Nevertheless, in spite of the questions that
remain andthe need for detailed pathways to be satisfactorily
drawn out, even Kalhan and Hanson [36]a c k n o w l e d g et h a t
“it is clear serine is a major amino acid in the overall
metabolism of a number of tumor-derived cell lines and is
critical for cell growth and proliferation.”
A l l o w i n gf o rag r e a t e ra m o u n to fs p e c u l a t i o n ,M u l l a r k y
etal.[6]contendthatanadditionalbenefitmaybederivedvia
diversionofglycolyticfluxintoserinebiosynthesisproducing
twice as much cytosolic NADH per glucose molecule as
compared with the production of pyruvate alone. If true,
t h e i rh y p o t h e s i sc o n t e n d st h a td e c r e a s e dN A D Hp r o d u c t i o n
i nt h ef a c eo fP H G D Hk n o c k d o w nw o u l di n d u c eaf o r m
of redox stress [6]. The problem is that, with less pyruvate
produced as glucose is abstracted from glycolysis at the
branchpointof3-phosphoglycerate,cellswithelevatedserine
biosynthesis would need a means to regenerate NAD
+.H o w
this is accomplished remains unclear. Mullarky et al. [6]
contend that perhaps the glycerol phosphate shuttle, which
ultimatelytransferselectronsfromcytosolic NADH to FAD
+
on mitochondrial electron transport chain complex II, may
provide a means. In such a situation, the purported pathway
couldprovideanadditionalbenefittocancercellsbyenabling
mitochondrialATPsynthesistooccurwithlessproductionof
reactiveoxygen species, passingtheelectronsfromNADHto
c o m p l e xI Ii n s t e a do fc o n v e n t i o n a lp a s s a g et oc o m p l e xI[ 6].
Finally, Mullen and DeBerardinis [1] succinctly note that
“beyond orchestrating a growth-promoting metabolic phe-
notype,evidencealsosuggeststhatPHGDH,whenexpressed
at high levels, may have properties that prime cells for
transformation.” Citing the work of Locasale et al. [8],
they point out that overexpression of catalytically active
PHGDH but not a hypomorphic mutant in breast epithelial
cells induced luminal filling, abnormal nuclear morphology,
anchorage-independence, and disturbed cell polarity—all
changes associated with cellular transformation in cancerous
cells.Suchobservations,weretheytobefurtherassessed,may
point to PHGDH overexpression as a means of “enhancing
the acquisition” of malignant properties [1].
Across all of these theories, the one thing that becomes
collectively clear is that although glycolysis, the TCA cycle,
and glutamine metabolism are central to the functioning of
normal, and at least to some extent cancerous, cells, they do
not act alone [6] .Th e ya r ep a r to fam u c hl a r g e rm e t a b o l i c
network through which enzymes such as PHGDH act to
alter the metabolism of the cell. Bearing this consideration
in mind, the oncogenic nature of PHGDH amplification
likely stems from “a combinatorial effect of pathway flux
toward biomass production, changes in redox status, energy
metabolism, and possibly some signaling functions” in
a manner that “likely varies based on environmental factors,
tissue of origin, and cooperating oncogenic mutations” [6].
If the historic progression of PHGDH understanding and
subsequent hypotheses to explain its effect has taught us
anything, it is that there is much that we still do not know.
7. Next Steps: Role as an Oncogene and
Argument for Therapeutics
Moving forward, the challenge will be to determine whether
or not cancer cells expressing elevated levels of PHGDH
require additional serine for growth. Evidence presented
throughout this paper speaks to a complicated and uncertain
r e s u l t ,f o r ,a sw eh a v es e e ni nt h ew o r ko fL o c a s a l ee ta l .
[8],higherlevelsofPHGDHassociatedwithenhancedserine
production in melanoma cells—an effect which could be
reversed via RNAi depletion of PHGDH. At the same time,
w o r kb yP o s s e m a t oe ta l .[ 21] found that breast cancer cells
with high levels of PHGDH expression are resistant to serine
withdrawal.LossoffunctionwithPHGDHknockdowncould
notberescuedwithadditionalserine[21].Rather,theauthors
noted a decrease in the level of aKG produced [21], a finding
that was not observed in melanoma cells [8]. A host of
mechanistic understandings further underscores the lack of
resolution to the question. It is a situation that has led
some scholars such as Luo [37]t os u g g e s tt h a tp u r p o r t e d
“addiction” to PHGDH observed in cancer cells might actu-
ally represent a set of distinct, albeit variable, “metabolic
addictions” with some cells (or cell lines) requiring serine
while others require aKG. Evidence from metabolic studies
has shown levels of multiple metabolites affected by PHGDH
knockdown. Where the discussion becomes interesting is
in the correspondingly consistent finding across multiple
types of cancer that PHGDH overexpression may directly
promote oncogenesis. Using a MCF-10A breast epithelial
cell morphogenesis 3D Matrigel assay, Locasale et al. [8]
revealed that overexpression of PHGDH increased cellular
proliferation rate and disrupted acinar structure such that
a change in cellular serine metabolism by way of PHGDH
may directly lead to altered phenotypic behavior in a manner
that favors transformation [37]. If true, the requirement of
additional serine for growth would hold weight, highlighting
theneedforfuturestudiestodeterminehowthishappensand
what it means in terms of the broader network of metabolic
mechanisms in cancer and the potential for PHGDH as a
metabolic oncogene [37].
Ongoingworkinthefieldhasbeguntoconsiderintersect-
ing pathways such as reported correlations between serine
biosynthesis and p73 expression in human lung adenocarci-
nomas[38]aswellaspossibler egula tio no fPH GDHb yEB V -
miR-BART1 in nasopharyngeal carcinomas involving con-
comitant overexpression of p130Cas and ERBB2 activation
[39] or by lack of repression from PKC𝜁 [40]. Recent work
by Ma et al. [40] provides compelling evidence that loss of
PKC𝜁 function in mice results in increased tumorigenesis
and heightened expression of PHGDH as well as PSAT1.
Mechanistically, crystal structures of PHGDH dimers reveal
phosphorylation sites at Ser55, Thr57, and Thr78 thought12 Journal of Oncology
to be highly conserved among humans, rats, monkeys, and
mice [40]. In prostate cancer, the enzyme has been found to
regulatec-Mycphosphorylation[41],andinhumanintestinal
tumor cells, it correlates with caspase-3 [40]. Additional
regulation of PHGDH has further been reported in the work
of Zhang et al. [42] and Al-Dhaheri et al. [43].
In terms of using PHGDH as a potential therapeutic
target, one would need to establish a significant difference
between the requirement of the enzyme’s activity in cancer
andinnormallyproliferatingcells[15].Overthelast30years,
studies have satisfied this objective, strongly implicating
P H G D Ha sa na t t r a c t i v ed r u gt a r g e ti nt h es u b s e to ft u m o r s
that amplify and overexpress its gene [37]. The important
determination will lie in whether or not a sufficient thera-
peutic window exists, given that serine biosynthesis operates
in all cells. Mitigating this concern, Luo [37] maintains that
PHGDHinhibitionremainsaviablecancertherapeutictarget
for two reasons: (1) a PHGDH inhibitor designed not to
cross the blood-brain barrier would not interfere with serine
homeostasisinthecentralnervoussystem,avoidingpotential
neurological effects reported for known PHGDH mutations
in humans, and (2) serine deficiency disorders can be treated
by exogenous serine supplement, whereas tumors’ addiction
to PHGDH might not be associated with serine flux. Thus,
a PHGDH inhibitor nonpermeable to the central nervous
systemcoupledwithserinesupplement(ifitcanbedesigned)
mayprovidethetherapeuticindexneededtoselectivelytarget
tumorigenic cells [37]. Considerable work remains to be
done before such a result could be achieved, particularly
t oe l u c i d a t et h ec o m p l e xp a t h w a ya n du n d e r l y i n gc o n t r o l
seemingly involved with PHGDH. As exemplified in recent
work by Chen et al. [44], the results of such studies are
far from clear and may ultimately depend on context- and
stage-specific factors. In light of these considerations and
thecomplexitiesrevealedbypreviousattemptstounderstand
metabolic PHGDH function using cancer cell lines and
tumor xenografts, it is thought that knock-in models in mice
may provide an alternative choice as an animal model with a
less confounded genetic background [44]. Regardless of the
specific model and experimental methodology used, work
remains to be done as researchers continue the ongoing pur-
suit of a potential therapeutic target and putative metabolic
oncogene.
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